COMP <GO>
TWST vs JNJ // NET PROFIT MARGIN
Twist Bioscience Corporation (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: TWST 4
— JNJ 8
▲ NET PROFIT MARGIN LEADER: JNJ
LAST: $129.04 (-15.54%) • MKT CAP: $10.13B
net-margins
-2.40%
LAST: $270.56 (-0.97%) • MKT CAP: $657.68B
net-margins
28.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TWST VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TWST | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 94.20% | 67.90% | +26.30 | TWST | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -11.70% | 25.50% | -37.20 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.66% | 2.97% | -3.63 | JNJ | /fcf-yield <GO> |
| Operating Margin | -4.20% | 34.70% | -38.90 | JNJ | /operating-margins <GO> |
| Net Profit Margin ACTIVE | -2.40% | 28.50% | -30.90 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 16.50% | 6.00% | +10.50 | TWST | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.59 | +20.41 | TWST | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.4 | 59.1 | -10.70 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.98 | 1.08 | -0.10 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 21.0x | 23.0x | -2.00 | TWST | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.13B | $657.68B | -$647.55B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TWST REV | JNJ REV | TWST GROSS % | JNJ GROSS % | TWST FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $381.5M | $94.19B | — | 67.9% | -$75.6M | $19.70B |
| FY 2024 | $618.3M | $88.82B | — | 69.1% | -$69.2M | $19.84B |
| FY 2023 | $608.0M | $85.16B | — | — | -$142.5M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TWST // BETA 0.98
JNJ // BETA 1.08